| Not Yet Recruiting | Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet Wit NCT07494266 | Karolinska Institutet | N/A |
| Not Yet Recruiting | Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study NCT07523867 | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Phase 4 |
| Not Yet Recruiting | Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil NCT07370194 | AstraZeneca | — |
| Recruiting | AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring NCT07210021 | AccurKardia, Inc. | — |
| Recruiting | Adding Urea to the Final Dialysis Fluid NCT06366230 | University of California, San Francisco | Phase 1 / Phase 2 |
| Recruiting | Hyperkalemia Quality Improvement Program (HK-QIP) Study NCT06884267 | AstraZeneca | N/A |
| Completed | Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG NCT07054905 | Kyungho Park | — |
| Recruiting | Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community NCT06940414 | Xiujuan Zang | — |
| Recruiting | Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age NCT05766839 | Vifor Pharma, Inc. | Phase 2 |
| Not Yet Recruiting | the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients NCT06736184 | Qianfoshan Hospital | Phase 4 |
| Completed | Nurse-Led Nutritional Education for Moroccan Dialysis Patients NCT07277530 | HASSAN 1st university | N/A |
| Not Yet Recruiting | Lower Vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Departme NCT06724991 | University of Malaya | N/A |
| Recruiting | A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia NCT07251309 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Phase 3 |
| Enrolling By Invitation | COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Usi NCT06763549 | Peerbridge Health, Inc | — |
| Recruiting | Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and NCT06365684 | Leiden University Medical Center | Phase 4 |
| Recruiting | Potassium Correction for RAAS Optimization in Chronic Kidney Disease NCT06256991 | University Medical Center Groningen | Phase 4 |
| Recruiting | Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes NCT06635590 | Saglik Bilimleri Universitesi | — |
| Completed | SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients NCT06029179 | Alexandria University | N/A |
| Recruiting | Dietary Potassium Liberalization in Pre-Dialysis Patients NCT05090865 | University of Manitoba | N/A |
| Completed | 5 Versus 10 Units of Insulin in Hyperkalemia Management NCT06036823 | Oman Medical Speciality Board | Phase 4 |
| Unknown | A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. NCT06277128 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Phase 2 |
| Terminated | Patiromer Trial in CKD Stage IIIB to V NCT05786469 | Mario Negri Institute for Pharmacological Research | Phase 3 |
| Completed | The Safety and Tolerability of WS016 in Healthy Chinese Volunteers NCT06281470 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Phase 1 |
| Completed | Tracking Treatment Pathways in Adult Patients With Hyperkalemia. NCT05408039 | AstraZeneca | — |
| Terminated | The ORTIZ Study: Optimising RASi Therapy With SZC NCT04983979 | Barts & The London NHS Trust | Phase 2 |
| Completed | An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Ki NCT05297409 | AstraZeneca | — |
| Completed | A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia NCT05535920 | NephroNet, Inc. | Phase 4 |
| Completed | A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG) NCT05441852 | Mayo Clinic | — |
| Completed | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects NCT05136664 | Vifor Fresenius Medical Care Renal Pharma | Phase 3 |
| Unknown | Lokelma for RAAS Maximisation in CKD & Heart Failure. NCT05004363 | St George's, University of London | Phase 3 |
| Completed | Dietary Fiber and Hyperkalemia in Dialysis Patients NCT05860491 | Qianfoshan Hospital | — |
| Completed | Artificial Intelligence Identified Dyskalemia Using Electrocardiogram (AIDE) NCT05118022 | National Defense Medical Center, Taiwan | N/A |
| Completed | Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassiu NCT05184998 | AstraZeneca | — |
| Unknown | Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. NCT05173584 | University of Aleppo | Phase 4 |
| Terminated | A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression i NCT05056727 | AstraZeneca | Phase 3 |
| Active Not Recruiting | OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure NCT04789239 | Michael Fu | Phase 2 |
| Completed | Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients NCT05029310 | Oslo University Hospital | Phase 4 |
| Completed | A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia NCT04955678 | Zeria Pharmaceutical | Phase 3 |
| Withdrawn | IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors NCT04510792 | Portsmouth Hospitals NHS Trust | — |
| Completed | Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients NCT05086185 | University of Nevada, Reno | — |
| Completed | Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis NCT04799067 | AstraZeneca | — |
| Completed | A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. NCT03528681 | AstraZeneca | Phase 3 |
| Terminated | Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chron NCT04847232 | AstraZeneca | Phase 3 |
| Completed | Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaem NCT04864795 | Vifor (International) Inc. | — |
| Unknown | Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial) NCT04727840 | Brigham and Women's Hospital | Phase 1 |
| Completed | A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia NCT04780841 | Ardelyx | Phase 2 |
| Completed | Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects NCT04217590 | AstraZeneca | Phase 3 |
| Completed | Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility St NCT04207203 | Karolinska Institutet | N/A |
| Terminated | Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management NCT04443608 | Comprehensive Research Associates | Phase 4 |
| Completed | Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients NCT04466969 | AstraZeneca | — |
| Completed | Clinical Potassium Pilot Study NCT04251468 | Medical University of Graz | N/A |
| Completed | Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electro NCT04256369 | King Faisal Specialist Hospital & Research Center | — |
| Recruiting | Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute H NCT04012138 | Nantes University Hospital | Phase 4 |
| Completed | Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients NCT03781089 | Duke University | Phase 4 |
| Completed | Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fra NCT04141800 | Spanish Society of Cardiology | — |
| Completed | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Hear NCT03888066 | Vifor Pharma, Inc. | Phase 3 |
| Active Not Recruiting | Targeted Potassium Levels for Prevention of ICD Therapy NCT03833089 | Rigshospitalet, Denmark | Phase 4 |
| Completed | Exploratory Study of ZG-801 for the Treatment of Hyperkalemia NCT03799926 | Zeria Pharmaceutical | Phase 2 |
| Terminated | Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On NCT03597035 | University Hospitals Cleveland Medical Center | Phase 4 |
| Completed | Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. NCT03183778 | NYU Langone Health | Phase 4 |
| Completed | A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) NCT03337477 | AstraZeneca | Phase 2 |
| Completed | A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potass NCT03303521 | AstraZeneca | Phase 3 |
| Completed | The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia NCT03326583 | Dominic Raj | Phase 2 |
| Completed | A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS NCT03283267 | AstraZeneca | Phase 1 |
| Completed | Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia NCT03172702 | AstraZeneca | Phase 3 |
| Completed | Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemi NCT03229265 | The Rogosin Institute | Phase 4 |
| Terminated | Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hy NCT03087058 | Vifor Pharma, Inc. | Phase 2 |
| Active Not Recruiting | Potassium Supplementation in CKD NCT03253172 | Erasmus Medical Center | N/A |
| Completed | ZS Ph2/3 Dose-response Study in Japan NCT03127644 | AstraZeneca | Phase 2 / Phase 3 |
| Completed | A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia NCT02875834 | AstraZeneca | Phase 3 |
| Completed | Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease NCT03071263 | Relypsa, Inc. | Phase 2 |
| Completed | A Multicenter Study to Evaluate the Nutritional Suitability of Renastart NCT02825784 | Vitaflo International, Ltd | N/A |
| Completed | The Effect of Mannitol on the Serum Potassium During Craniotomy NCT03161977 | The Affiliated Hospital of Xuzhou Medical University | — |
| Terminated | A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia NCT03018067 | Ardelyx | Phase 2 |
| Unknown | Measurement of Serum Potassium Rate During Accidental Hypothermia. NCT03096561 | University Hospital, Grenoble | N/A |
| Completed | Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy NCT05382988 | Guangdong Provincial People's Hospital | Phase 3 |
| Completed | Patiromer With or Without Food for the Treatment of Hyperkalemia NCT02694744 | Relypsa, Inc. | Phase 4 |
| Completed | REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observati NCT02607085 | ZS Pharma, Inc. | — |
| Completed | POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Stu NCT02609841 | ZS Pharma, Inc. | — |
| Completed | Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair NCT02483702 | Valley Anesthesiology Consultants | N/A |
| Completed | Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months NCT02163499 | ZS Pharma, Inc. | Phase 3 |
| Completed | Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalem NCT02107092 | ZS Pharma, Inc. | Phase 3 |
| Completed | Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. NCT02088073 | ZS Pharma, Inc. | Phase 3 |
| Completed | Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns NCT01349218 | The University of Texas Health Science Center, Houston | N/A |
| Completed | Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients NCT02065076 | Maisonneuve-Rosemont Hospital | Phase 4 |
| Completed | Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions NCT02020317 | University of Zurich | N/A |
| Terminated | Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia NCT01866709 | ZS Pharma, Inc. | Phase 4 |
| Completed | Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia NCT01737697 | ZS Pharma, Inc. | Phase 3 |
| Completed | Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyp NCT01493024 | ZS Pharma, Inc. | Phase 2 |
| Completed | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN NCT01371747 | Relypsa, Inc. | Phase 2 |
| Completed | Evaluation of Patiromer in Heart Failure Patients NCT00868439 | Relypsa, Inc. | Phase 2 |
| Terminated | An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Part NCT02033317 | Relypsa, Inc. | Phase 2 |
| Completed | Early Protein Supplementation on Prevention of Hyperkalemia NCT00290160 | The University of Texas Health Science Center at San Antonio | N/A |
| Unknown | Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation NCT00162487 | Hadassah Medical Organization | N/A |